Tadalafil Tablet, Film Coated
Product Images NDC 68071-3777

Product Visual Gallery

This gallery contains 12 technical images submitted to the FDA as part of the official labeling for Tadalafil (NDC 68071-3777). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Nucare Pharmaceuticals,inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Image (2c3d64d3 27b6 4ec1 Bd71 7c6bab4cd31d 01)

Chemical structure diagram of tadalafil, showing its molecular framework with labeled bonds and key ring structures. The image illustrates the arrangement of atoms characteristic of tadalafil's chemical composition.*

FDA Label Image

Image (2c3d64d3 27b6 4ec1 Bd71 7c6bab4cd31d 02)

Four line graphs showing differences in blood pressure measurements between tadalafil and placebo over time. The graphs compare standing systolic and diastolic blood pressure and supine systolic and diastolic blood pressure, with values plotted against time in hours up to 96 hours.*

FDA Label Image

Image (2c3d64d3 27b6 4ec1 Bd71 7c6bab4cd31d 03)

A dual line chart showing changes in systolic blood pressure (mmHg) over 24 hours post-dose. The top panel displays standing systolic blood pressure while the bottom panel shows supine systolic blood pressure. Two treatments are compared: tadalafil 20 mg with doxazosin 8 mg, and placebo with doxazosin 8 mg, with time in hours on the x-axis and blood pressure change on the y-axis.*

FDA Label Image

Image (2c3d64d3 27b6 4ec1 Bd71 7c6bab4cd31d 04)

A line graph comparing systolic blood pressure changes over 12 hours after administration of 20 mg tadalafil versus placebo, both with 8 mg daily doxazosin, measured at 08:00 and 20:00 time points. The x-axis shows time after administration in hours; the y-axis shows systolic blood pressure changes in mmHg.*

FDA Label Image

Image (2c3d64d3 27b6 4ec1 Bd71 7c6bab4cd31d 05)

A pharmacokinetic graph showing plasma tadalafil concentration (µg/L) on the Y-axis versus time (hours) on the X-axis. It compares three conditions: single 20-mg dose, single 5-mg dose, and once-daily 5-mg dose after 5 days, illustrated with separate line markers including error bars for variability.*

FDA Label Image

Image (2c3d64d3 27b6 4ec1 Bd71 7c6bab4cd31d 06)

A line graph comparing change from baseline in IPSS total score over treatment duration in weeks for tadalafil 5 mg versus placebo. The graph shows a greater decrease in IPSS score for tadalafil compared to placebo across 0, 4, 8, and 12 weeks, with statistical significance noted at p<0.01.*

FDA Label Image

Image (2c3d64d3 27b6 4ec1 Bd71 7c6bab4cd31d 07)

A line graph comparing the change from baseline in IPSS total score over a 12-week treatment duration, contrasting tadalafil 5 mg and placebo groups. The graph shows score reductions for both groups, with tadalafil exhibiting a greater decrease. Statistical significance (p<0.01) is noted at certain timepoints.*

FDA Label Image

Image (2c3d64d3 27b6 4ec1 Bd71 7c6bab4cd31d 08)

A line graph showing the least-squares mean change from baseline over weeks of therapy (0, 4, 12, and 26) comparing Tadalafil/Finasteride versus Placebo/Finasteride. The graph plots mean changes with markers and includes statistical significance annotations for several points indicating p-values less than 0.001 and 0.05.*

FDA Label Image

Image (2c3d64d3 27b6 4ec1 Bd71 7c6bab4cd31d 09)

A line graph comparing the change from baseline in IPSS total score over 12 weeks of treatment between Tadalafil 5 mg and placebo. The x-axis shows duration of treatment in weeks, and the y-axis shows change from baseline score. Tadalafil shows a greater reduction in IPSS score compared to placebo.*

FDA Label Image

Unichem Logo (2c3d64d3 27b6 4ec1 Bd71 7c6bab4cd31d 10)

FDA Label Image

Image (2c3d64d3 27b6 4ec1 Bd71 7c6bab4cd31d 11)

FDA Label Image

Pdp (68071 3777 5)

Tadalafil 20 mg film-coated tablets label from NuCare Pharmaceuticals, Inc. The label indicates #15 tablets per package with the product number P2213015. It describes the tablet as almond-shaped, yellow, debossed with '289' on one side and 'U' on the other. The label also includes lot, serial, expiration date placeholders, and storage instructions at controlled temperatures 68-77°F.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.